None listed
Conditions
Brief summary
The aim of this study is to determine how common retrograde ejaculation is in patients following retroperitoneal lymph node dissection for the treatment of testicular cancer and the impacts that this might have on quality of life. Who is it for? You may be eligible for this study if you are aged 18 years or older, have a confirmed diagnosis of a testicular germ cell tumour, have received retroperitoneal lymph node dissection at least 6 months ago. Study details All participants will be invited to complete a once-off series of questionnaires assessing quality of life, which is expected to take around 20 minutes to complete. Additionally, participants will be invited to partake in an optional semi-structured interview, which will last up to 45 minutes and will occur at a later time. It is hoped that this study will contribute important data to help understand the impact of retrograde ejaculation following retroperitoneal lymph node dissection has on survivors of testicular cancer.
Interventions
PREPARE Part A is a prospective, observational cohort study enrolling any individual who underwent retroperitoneal lymph node dissection (RPLND) at least six months prior for management of testicular cancer. After consent and confirmation of eligibility, eligible participants will complete a once-off series of health-related quality of life (HRQoL) questionnaires either online or on paper to inform the prevalence of retrograde ejaculation and impact (if any) of retrograde ejaculation on HRQoL. I
PREPARE Part A is a prospective, observational cohort study enrolling any individual who underwent retroperitoneal lymph node dissection (RPLND) at least six months prior for management of testicular cancer. After consent and confirmation of eligibility, eligible participants will complete a once-off series of health-related quality of life (HRQoL) questionnaires either online or on paper to inform the prevalence of retrograde ejaculation and impact (if any) of retrograde ejaculation on HRQoL. It is anticipated that completion of the questionnaires will take up to 20 minutes. Participants will also be invited to participate in an optional, semi-structured interview, which will last up to 45 minutes. This will be coordinated at a time convenient to the participant at a later fate.
Sponsors
Peter MacCallum Cancer Centre
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Participants must meet all the following criteria for study entry: 1. Participant has provided written, informed consent OR electronic, informed consent sighted by an investigator, on Telehealth. 2. Males greater than or equal to 18 years at time of informed consent. 3. Histologically confirmed testicular germ cell tumour (based on archival tissue report) 4. Retroperitoneal lymph node dissection for management of testicular cancer at least six months prior to consent. 5. Participant is willing and able to comply with the protocol for the duration of the study including treatment, and scheduled visits and examination including follow up.
Exclusion criteria
Participants who meet any of the following criteria will be excluded from study entry: 1. Currently receiving treatment or planning to receive treatment within two months (i.e., surgery, chemotherapy, radiotherapy) for testicular cancer (or other malignancy). 2. Known medical condition or other issue that in the opinion of the investigator, that would affect adherence to study requirements.
Outcome results
None listed